IMMUTEP LIMITED - AMER

Immutep Reveals a New Anti-LAG-3 Research Program

08 6 2021 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021

04 6 2021 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021

04 6 2021 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor

02 6 2021 08:00:02 提供 Nasdaq GlobeNewswire

Immutep Enters Into A New Collaboration With Merck KGaA, Darmstadt, Germany For LAG-3 Therapy, Efti

01 6 2021 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Granted Chinese Patent For Eftilagimod Alpha In Chemo-Immunotherapy Combination

26 5 2021 08:00:01 提供 Nasdaq GlobeNewswire

Immutep To Present At The Jefferies Virtual Healthcare Conference

25 5 2021 08:00:04 提供 Nasdaq GlobeNewswire

Immutep Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting

20 5 2021 08:00:02 提供 Nasdaq GlobeNewswire

Immutep Operational Update

07 5 2021 08:00:00 提供 Nasdaq GlobeNewswire

Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting

28 4 2021 10:21:40 提供 Nasdaq GlobeNewswire